作者：
Paul E,Goss [1]
;
James N,Ingle [1]
;
Kathleen I,Pritchard [1]
;
Nicholas J,Robert [1]
;
Hyman,Muss [1]
;
Julie,Gralow [1]
;
Karen,Gelmon [1]
;
Tim,Whelan [1]
;
Kathrin,Strasser-Weippl [1]
;
Sheldon,Rubin [1]
;
Keren,Sturtz [1]
;
Antonio C,Wolff [1]
;
Eric,Winer [1]
;
Clifford,Hudis [1]
;
Alison,Stopeck [1]
;
J Thaddeus,Beck [1]
;
Judith S,Kaur [1]
;
Kate,Whelan [1]
;
Dongsheng,Tu [1]
;
Wendy R,Parulekar [1]
作者单位：
From the Massachusetts General Hospital Cancer Center, Avon International Breast Cancer Research Program (P.E.G.), Harvard Medical School (P.E.G., E.W.), and Dana-Farber Cancer Institute (E.W.), Boston; the Department of Oncology, Mayo Clinic, Rochester, MN (J.N.I., J.S.K.); Sunnybrook Odette Cancer Centre, Toronto (K.I.P.), British Columbia Cancer Agency, Vancouver (K.G.), Canadian Cancer Trials Group, Queen's University, Kingston, ON (K.W., D.T., W.R.P.), Department of Oncology, McMaster University, Hamilton, ON (T.W.), and Dalhousie University Faculty of Medicine, Moncton Hospital, Moncton, NB (S.R.) - all in Canada; Virginia Cancer Specialists-US Oncology Network, Fairfax (N.J.R.); University of North Carolina-Lineberger Comprehensive Cancer Center, Chapel Hill (H.M.); University of Washington School of Medicine, Seattle (J.G.); Center of Oncology and Hematology, Wilheminen Hospital, Vienna (K.S.-W.); Colorado Cancer Research Program, Denver (K.S.); Johns Hopkins Kimmel Cancer Center, Baltimore (A.C.W.); Memorial Sloan Kettering Cancer Center, New York (C.H.); University of Arizona, Tucson (A.S.); and Highlands Oncology Group, Fayetteville, AR (J.T.B.).
[1]
DOI
10.1056/NEJMoa1604700
PMID
27264120
发布时间
2024-06-10
换一批
换一批
